Tenax Therapeutics (TENX) FCF Margin (2011 - 2015)

Tenax Therapeutics (TENX) posted quarterly FCF Margin of 6810.14% for Q2 2015, down 757.08% on a QoQ basis from 794.57% in Q2 2013.

Tenax Therapeutics (TENX) FCF Margin (2011 - 2015) Analysis & Trends

Tenax Therapeutics has reported FCF Margin for 5 years, with the latest figure at 6810.14% in Q2 2015.

FCF Margin for Q2 2015 came in at 6810.14%, changed N/A year-over-year; the trailing twelve-month figure through Jun 2016 was 41810.97% (down 4146428.0% YoY), and the FY2015 annual result was 19788.64%, down 1626333.0% from the prior year.
FCF Margin eased to 6810.14% in Q2 2015, from 794.57% in the prior quarter.
Over five years, FCF Margin peaked at 219.27% in Q4 2012 and troughed at 9737.26% in Q1 2011.
A 4-year average of 3319.56% and a median of 1535.46% in 2012 frame the typical range for FCF Margin.
The widest annual swing landed in 2012, when FCF Margin surged 820179 bps; it then jumped 70007 bps in 2013.
A 4-year view of FCF Margin shows it stood at 2667.66% in 2011, then soared by 92 bps to 219.27% in 2012, then sank by 262 bps to 794.57% in 2013, then tumbled by 757 bps to 6810.14% in 2015.
Per Business Quant data, the three most recent FCF Margin figures were 6810.14% in Q2 2015, 794.57% in Q2 2013, and 333.3% in Q1 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	139.03 Bn	131.18 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	85.64 Bn	77.64 Bn	3.93 Bn	13.35%
3	Argenx Se	64.93 Bn	59.75 Bn	1.37 Bn	-
4	Moderna	57.93 Bn	52.80 Bn	52.00 Mn	-388.28%
5	BeOne Medicines	41.95 Bn	36.86 Bn	1.53 Bn	25.68%
6	Alnylam Pharmaceuticals	31.51 Bn	28.20 Bn	992.69 Mn	22.62%
7	BioNTech SE	28.00 Bn	9.60 Bn	668.28 Mn	41.07%
8	Insmed	27.42 Bn	26.26 Bn	358.27 Mn	-22.35%
9	Royalty Pharma	27.29 Bn	26.45 Bn	-	70.82%
10	Tenax Therapeutics	78.30 Mn	78.30 Mn	-	-

Download Data